National Health Commission Key Laboratory of Systems Biology of Pathogens and.
Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Am J Respir Crit Care Med. 2020 Sep 1;202(5):717-729. doi: 10.1164/rccm.201908-1567OC.
Respiratory syncytial virus (RSV) is the leading cause of childhood respiratory infections worldwide; however, no vaccine is available, and treatment options are limited. Identification of host factors pivotal to viral replication may inform the development of novel therapies, prophylaxes, or diagnoses. To identify host factors involved in RSV replication and to evaluate their potential for disease management. A gain-of-function screening was performed on the basis of a genome-wide human complementary DNA library screen for host factors involved in RSV replication. The antiviral mechanism of CXCL4 (chemokine [C-X-C motif] ligand 4) was analyzed. Its clinical role was evaluated via nasopharyngeal aspirates and plasma samples from patients with RSV infection and different disease severities. Forty-nine host factors restricting RSV replication were identified by gain-of-function screening, with CXCL4 showing the strongest antiviral effect, which was secretion dependent. CXCL4 blocked viral attachment through binding to the RSV main receptor heparan sulfate, instead of through interacting with RSV surface proteins. Intranasal pretreatment with CXCL4 alleviated inflammation in RSV-infected mice, as shown by decreased concentrations of tumor necrosis factor and viral load in BAL fluid samples as well as by viral nucleocapsid protein histological staining in lungs. Compared with non-RSV infections, RSV infections induced elevated CXCL4 concentrations both in plasma and airway samples from mice and pediatric patients. The airway CXCL4 concentration was correlated with viral load and disease severity in patients ( < 0.001). Our results suggest that CXCL4 is an RSV restriction factor that can block viral entry and serve as an indicator of clinical severity in RSV infections.
呼吸道合胞病毒(RSV)是全球儿童呼吸道感染的主要原因;然而,目前尚无可用的疫苗,治疗选择也有限。确定对病毒复制至关重要的宿主因素可能有助于开发新的治疗方法、预防措施或诊断方法。为了确定参与 RSV 复制的宿主因素,并评估其在疾病管理中的潜在作用。根据参与 RSV 复制的宿主因素的全基因组人 cDNA 文库筛选,进行了功能获得性筛选。分析了 CXCL4(趋化因子[C-X-C 基序]配体 4)的抗病毒机制。通过对 RSV 感染和不同疾病严重程度患者的鼻咽抽吸物和血浆样本进行分析,评估了其临床作用。通过功能获得性筛选鉴定了 49 种限制 RSV 复制的宿主因素,其中 CXCL4 的抗病毒作用最强,且依赖于其分泌方式。CXCL4 通过与 RSV 主要受体肝素硫酸结合而不是与 RSV 表面蛋白相互作用来阻断病毒附着。CXCL4 预处理可减轻 RSV 感染小鼠的炎症,这表现在 BAL 液样本中肿瘤坏死因子和病毒载量降低,以及肺部病毒核衣壳蛋白组织学染色减少。与非 RSV 感染相比,RSV 感染可同时诱导小鼠和儿科患者的血浆和气道样本中 CXCL4 浓度升高。患者气道 CXCL4 浓度与病毒载量和疾病严重程度相关( < 0.001)。我们的研究结果表明,CXCL4 是一种 RSV 限制因子,可阻断病毒进入,并可作为 RSV 感染临床严重程度的指标。